Amgen, Adaptive Partner In COVID-19 Neutralizing Antibody R&D Effort

 
• By Joseph Haas

The companies are combining their technologies to seek neutralizing antibody therapeutics that could prevent or treat COVID-19, building on their previous partnership in monitoring minimal residual disease in blood cancers.

SC2004_Research Team_1039502866_1200.jpg
Amgen and Adaptive are combining their expertise to seek a neutralizing antibody fight COVID-19

More from COVID-19

More from Scrip